Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$7.07 – $8.32
22% from low
Exchange
OTC Link
ADRC
Borrow rate
0.25%
Easy to borrow
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $159.08B | $186.57B | $191.91B | $215.82B | $231.98B | $260.30B | $275.25B | $283.58B |
| Cost of revenue | $136.52B | $159.75B | $164.47B | $187.28B | $201.49B | $228.97B | $244.62B | $253.16B |
| Gross profit | $22.56B | $26.81B | $27.44B | $28.54B | $30.49B | $31.33B | $30.63B | $30.42B |
| Gross margin | 14.2% | 14.4% | 14.3% | 13.2% | 13.1% | 12.0% | 11.1% | 10.7% |
| R&D | $1.06B | $1.35B | $1.66B | $1.99B | $2.11B | $2.20B | $2.39B | $2.34B |
| Operating income | $5.21B | $8.93B | $7.18B | $8.21B | $9.01B | $7.67B | $8.14B | $9.94B |
| EBITDA | $6.72B | $9.35B | $9.94B | $11.27B | $12.42B | $10.90B | $12.06B | $14.37B |
| Net income | $3.88B | $4.08B | $4.50B | $5.09B | $5.62B | $3.77B | $4.55B | $5.72B |
| Net margin | 2.4% | 2.2% | 2.3% | 2.4% | 2.4% | 1.4% | 1.7% | 2.0% |
| EPS (diluted) | 6.85 | 7.20 | 7.90 | 8.95 | 8.05 | 5.10 | 6.15 | 7.70 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $298.0B | $0.00 | $0.00–$0.00 | 0 |
| 2027 | $317.4B | $0.00 | $0.00–$0.00 | 0 |
Forward consensus · source: Financial Modeling Prep
SHANGHAI PHARMS UNSP/ADR
No one on the platform currently holds SHPMY.
No tracked institution reports a position in SHPMY as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-07-16 | $0.2572 | 2026-09-14 |
| 2025-12-31 | $0.0844 | 2026-02-23 |
| 2025-07-17 | $0.2025 | 2025-09-09 |
| 2024-09-19 | $0.0561 | 2024-11-12 |
| 2024-07-19 | $0.2819 | 2024-09-11 |
| 2023-07-17 | $0.4222 | 2023-09-12 |
No one on the platform has traded SHPMY yet.
| $5.6B |
| — |
| GZPHFGuangzhou Baiyunshan Pharmaceutical Holdings Company Limited | $2.34 | +0.00% | $6.2B | — |
| MSMKFMatsukiyoCocokara & Co. | $14.60 | +0.00% | $5.7B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 1.3× earnings vs its 1.1× historical median P/E.
Fair value ≈ $6.21 · price $7.34 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.